01
01 · WHAT IT IS
A naturally occurring tripeptide (Lys-Pro-Val) — the C-terminal fragment of α-MSH — studied for anti-inflammatory signaling, gut-barrier research, mast-cell stabilization, and skin-calming pathways.
BLUEPRINT RESEARCH GUIDE
◆ Research Compound · KPV · Anti-Inflammatory Tripeptide ◆
KPV
The off-switch the inflamed gut and irritated immune system have been waiting for.
KPV is the last three amino acids of α-MSH — Lysine, Proline, Valine — and that short tail is where most of the anti-inflammatory action lives. It enters cells, shuts down NF-κB at the source, and quiets the cytokine cascade that drives gut inflammation, eczema, mast-cell flares, and chronic skin irritation. No pigmentation. No melanocortin receptor activation. Just the brake on inflammation.
Scroll · Inspect
Educational Overview
Watch: KPV Explained in 60 Seconds
A quick, simple breakdown of what KPV is, why researchers study it, how it works, and what makes it unique.
02
02 · HOW IT WORKS
KPV is studied for its relationship to NF-κB suppression, mast cell stabilization, and downstream cytokine modulation — without the pigmentation effects of full-length α-MSH.
03
03 · WHY IT MATTERS
KPV connects multiple high-interest research areas into one compound — gut inflammation, skin irritation, immune over-reactivity, and post-flare recovery research.
Designed to help visitors understand the product before exploring the full research guide.
Primer · First Principles
WHAT'S
KPV,
REALLY?
Think of KPV as the off-switch on the inflammation amplifier — a tripeptide that walks into the cell and turns down NF-κB before the cytokine cascade even starts.
Most anti-inflammatory tools work downstream — blocking a single cytokine, suppressing a receptor, masking the symptom. KPV works at the transcription level: it enters the cell, binds within, and suppresses NF-κB translocation. That single upstream brake quiets IL-1, IL-6, TNF-α, and the mast-cell histamine cascade simultaneously.
The result is broad-spectrum inflammatory calm — without immunosuppression. The gut barrier rebuilds. Skin irritation cools. Mast-cell reactivity drops. The body's own resolution machinery gets to finish the job.
The One Thing To Remember
"Think of KPV as NF-κB turned down at the source — the inflammation amplifier quieted, the cytokine storm never triggered, the resolution pathway free to do its work."
It doesn't suppress the immune system. It restores the upstream off-switch the immune system depends on to stop a flare.
Problem · Agitation
WHY YOUR BODY MISSES THIS SO BADLY
Chronic inflammation isn't a single problem. It's the same upstream signal — NF-κB stuck on — expressing in the gut, the skin, and the mast cells simultaneously.
01 / Gut
GUT BARRIER STAYS LEAKY
Chronic intestinal inflammation degrades tight junctions. Endotoxin crosses into circulation, fueling systemic inflammation that never resolves.
02 / Skin
SKIN STAYS REACTIVE
Eczema, psoriasis, and chronic dermatitis are downstream of mast-cell and NF-κB overactivity. Topical steroids mask, but the upstream signal keeps firing.
03 / Mast Cells
MAST CELLS WON'T STAND DOWN
Mast-cell activation drives histamine, tryptase, and cytokine release — fueling chronic flushing, itching, GI distress, and food reactivity loops.
04 / Cytokines
CYTOKINES STAY ELEVATED
IL-1, IL-6, and TNF-α stay chronically elevated, driving fatigue, joint pain, brain fog, and the slow-burn inflammation behind most chronic disease.
Mechanism · How It Works
ONE PEPTIDE. THREE CASCADES.
Subcutaneous KPV enters circulation, penetrates cells directly, and modulates inflammation at the transcription level — upstream of cytokine release.
01 · NF-κB
MASTER SWITCH SUPPRESSED
KPV enters the cell nucleus and suppresses NF-κB translocation. The single upstream signal that drives the cytokine cascade is quieted — before IL-1, IL-6, and TNF-α are ever transcribed.
→
02 · Mast Cells
DEGRANULATION STABILIZED
KPV stabilizes mast cells, reducing histamine and tryptase release. Flushing, itching, and reactivity loops calm without antihistamine sedation.
→
03 · Barrier
EPITHELIAL REPAIR ACCELERATES
With inflammation quieted, gut and skin barriers regenerate. Tight junctions reform, transepithelial resistance rises, the body's own resolution pathway finishes the job.
That's it. NF-κB suppressed, mast cells stable, barriers repairing — broad inflammatory calm without immunosuppression.
The Dream State
WHAT CHANGES WHEN IT ENTERS THE SYSTEM
Downstream effects of suppressing inflammation at the source.
GUT INFLAMMATION DROPS
Studied for IBD-like models, leaky gut, and post-flare recovery. The intestinal lining gets the quiet it needs to rebuild.
SKIN IRRITATION COOLS
Eczema, psoriasis, and chronic dermatitis research shows reduced redness, itch, and flare frequency — topical and systemic.
MAST CELL REACTIVITY DROPS
Flushing, itching, food reactivity, and MCAS-pattern symptoms soften as mast cells stabilize.
CYTOKINE LOAD LOWERS
IL-1, IL-6, and TNF-α suppression reduces the slow-burn inflammation behind fatigue, joint pain, and brain fog.
BARRIER INTEGRITY RETURNS
Tight junctions reform in gut and skin. Transepithelial resistance rises. Endotoxin leakage drops.
NO IMMUNOSUPPRESSION
Unlike steroids or biologics, KPV modulates rather than suppresses. The immune system stays functional.
NO PIGMENTATION EFFECTS
Unlike full-length α-MSH or Melanotan, KPV does not activate melanocortin receptors. No tanning, no darkening, no MC1R binding.
CLEAN, BROAD-SPECTRUM CALM
One upstream brake. Multiple downstream improvements. No accumulation, no withdrawal, no rebound flare.
Future Pacing · Timeline
WHAT YOU'LL ACTUALLY NOTICE
Not biomarkers. The lived experience — day by day — on a consistent daily protocol.
D 1-3
DAY 1–3
First doses. Subtle drop in gut reactivity. Skin feels less hot. Itch and flush episodes briefer. No sedation.
WK 1-2
WEEK 1–2
Gut symptoms calmer. Stool quality improves. Skin redness drops. Mast-cell reactivity to triggers softens.
WK 3-4
WEEK 3–4
Barrier integrity improves. Food reactivity narrows. Systemic inflammation markers trend down. Energy returns as cytokine load lowers.
WK 4+
BEYOND WEEK 4
Stable calm inflammatory baseline. Cycle off — improvements persist as the resolution pathway finishes its work without continuous dosing.
Reconstitution
KPV 10 mg Reconstitution.
Exact measurements based on 10 mg vial + 2 mL bacteriostatic water.
- 1Wipe both vial tops — your 10 mg KPV vial and your bacteriostatic water — with an alcohol pad.
- 2Draw 2 mL of bacteriostatic water into a sterile syringe.
- 3Inject the water slowly down the inside wall of the KPV vial.
- 4Swirl gently until fully dissolved. Solution is clear. Do not shake.
- 5Refrigerate. Label with reconstitution date. Stable for ~30 days refrigerated.
Concentration
10 mg ÷ 2 mL
= 5 mg/mL
= 50 mcg per U-100 unit tick
Live Protocol Calculator
Protocol Math Made Simple.
Change any input. Every value below updates automatically from the formula. No guessing.
Draw
20 units
Volume
0.20 mL
Dose Equivalent
= 1 mg
Concentration
5 mg/mL
mg / unit
50 mcg
Weekly mg
7 mg
Weeks / vial
1.4 wk
Cycle total
28 mg
Vials needed
3
U-100 Syringe Quick Reference · at standard concentration
10 units
= 500 mcg
20 units
= 1 mg
50 units
= 2.50 mg
100 units
= 5 mg
Dosing Tiers
Three Commonly Researched Tiers.
Units, weeks per vial, and vials per cycle — all derived from your 10 mg vial + 2 mL BAC water.
Weekly Schedule
The Standard Weekly Plan.
Daily subcutaneous injection. Morning dose preferred. Effects build over 1–2 weeks; full barrier and inflammation benefit by week 4.
MON
AM
20 units
STANDARD DOSE
= 1 mg
ABDOMEN
TUE
AM
20 units
STANDARD DOSE
= 1 mg
ABDOMEN
WED
AM
20 units
STANDARD DOSE
= 1 mg
ABDOMEN
THU
AM
20 units
STANDARD DOSE
= 1 mg
ABDOMEN
FRI
AM
20 units
STANDARD DOSE
= 1 mg
ABDOMEN
SAT
AM
20 units
STANDARD DOSE
= 1 mg
ABDOMEN
SUN
AM
20 units
STANDARD DOSE
= 1 mg
ABDOMEN
Best Time Of Day
When Researchers Typically Dose.
Morning
PREFERREDReasons
- Consistent AM timing improves adherence
- Supports daytime anti-inflammatory profile
- Simplifies site rotation
Early Afternoon
Timing is flexible; effect is systemic.
Cycle Length
Standard Cycle Planning.
ACTIVE CYCLE
4
weeks
OFF CYCLE
2
weeks
Common research window is 4–6 weeks on, then 2 weeks off. KPV modulates inflammatory signaling — continuous long-term use is not the standard pattern.
Full Standard Cycle
4 weeks · approximately 3 vials
Long-Term Supply
How Long Will One Vial Last?
Based on the Standard tier: 1 mg × 7/week = 7.00 mg per week. One 10 mg vial lasts approximately 1.4 weeks.
1 month
4
vials
3 months
10
vials
6 months
19
vials
9 months
28
vials
12 months
37
vials
Assumes continuous weekly dosing at the Standard tier. Vials rounded up.
Cycle Planner
Plan the Full Cycle Before Ordering.
Units / dose
20
Doses / week
7
Weeks / vial
1.4
Total vials needed
3
You currently have 1 vial · Coverage 33% · Add 2 more to complete the plan.
Add Missing Vials (2) →Complete Starter Plan
Start With Enough To Complete the Plan.
One vial may not cover a full standard cycle. Use the standard-cycle supply option to complete the full protocol without interruption.
Research Timeline
What Researchers Typically Monitor Across The Full 4-Week Cycle.
Educational context only. This is not a guarantee of outcomes.
01 / 04
The Stack Multiplier
The Top 3 Peptides To Stack With KPV.
KPV quiets inflammation at the source. Paired with the right co-signals, gut, skin, and immune recovery all reinforce each other.
#1
BPC-157
The Gut-Repair Partner
KPV quiets inflammation; BPC-157 rebuilds the gut lining underneath. The complete gut protocol.
#2
Thymosin Alpha-1
The Immune Modulator
KPV quiets local inflammation; Thymosin Alpha-1 modulates the underlying immune tone.
#3
Glutathione
The Antioxidant Layer
KPV drops inflammation; glutathione clears the oxidative load inflammation created.
Educational research information only. Not medical advice. Values shown are derived from the vial strength and BAC water amount using standard U-100 syringe math. Verify with a qualified professional.
Frequently Asked
KPV Questions
What does this peptide do?+
KPV is the C-terminal tripeptide fragment of α-MSH (Lys-Pro-Val). It suppresses NF-κB at the transcription level, stabilizes mast cells, and reduces downstream cytokines — quieting inflammation across gut, skin, and immune pathways without immunosuppression or pigmentation effects.
How long does it take to work?+
Subtle reductions in gut and skin reactivity within 3–7 days. Meaningful barrier and inflammation improvements over 2–4 weeks. Full cycle effect at 4–6 weeks.
What is the normal dosage, frequency, and cycle length?+
Standard: 1 mg subcutaneously daily, morning. Range 0.5–2 mg. Cycle 4–6 weeks on, 2–4 weeks off. Oral and topical preparations also exist for targeted gut or skin protocols.
Is it safe, and what are the possible side effects?+
Well-tolerated in research literature. Possible: mild injection-site irritation. No pigmentation effects (unlike Melanotan / full α-MSH), no immunosuppression, no documented dependence or withdrawal.
How do I know it is high quality?+
Every batch of our KPV is independently third-party tested for purity (>99%), peptide identity via HPLC and mass spectrometry, and endotoxin levels. A Certificate of Analysis is available for the exact lot you receive. We ship from a temperature-controlled facility in San Diego.
EVERY YEAR YOU WAIT, CHRONIC INFLAMMATION REWIRES GUT, SKIN, AND IMMUNE FUNCTION DEEPER.
NF-κB stays stuck on. Barriers stay leaky. Mast cells stay reactive. The inflammatory baseline becomes the new normal. KPV restores the upstream off-switch the resolution pathway depends on.
QUIET INFLAMMATION AT THE SOURCE.
Research-grade KPV, 10 mg per vial. Third-party tested. The anti-inflammatory tripeptide without the trade-off.
Explore KPV— SOURCE RESEARCH-GRADE
RESEARCH-GRADE KPV
Source KPV from Blueprint Peak Performance — third-party tested for >99% purity, cold-chain handled, shipped from San Diego. Educational research use only.
Blueprint Research Guide is editorial. The link above sources research-grade compounds from Blueprint Peak Performance — an independent supplier. For educational purposes only. Research use only — not for human consumption, treatment, or diagnosis.